Nurix Therapeutics Inc.is a biopharmaceutical company. It focuses on the discovery, development and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company's product candidates include NX-2127 and NX-1607 which are in clinical stage. Nurix Therapeutics Inc.is based in San Francisco, California.
| Revenue (Most Recent Fiscal Year) | $83.98M |
| Net Income (Most Recent Fiscal Year) | $-264.46M |
| PE Ratio (Current Year Earnings Estimate) | 21.18 |
| PE Ratio (Trailing 12 Months) | 10.57 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 3.80 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.62 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | 43.91% |
| Net Margin (Trailing 12 Months) | 42.01% |
| Return on Equity (Trailing 12 Months) | 49.34% |
| Return on Assets (Trailing 12 Months) | 38.61% |
| Current Ratio (Most Recent Fiscal Quarter) | 8.44 |
| Quick Ratio (Most Recent Fiscal Quarter) | 8.44 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $5.29 |
| Earnings per Share (Most Recent Fiscal Quarter) | $4.73 |
| Earnings per Share (Most Recent Fiscal Year) | $-3.05 |
| Diluted Earnings per Share (Trailing 12 Months) | $2.31 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 109.25M |
| Free Float | 101.93M |
| Market Capitalization | $2.67B |
| Average Volume (Last 20 Days) | 2.17M |
| Beta (Past 60 Months) | 1.82 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 6.70% |
| Percentage Held By Institutions (Latest 13F Reports) | 0.00% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |